ID   MK12_HUMAN              Reviewed;         367 AA.
AC   P53778; Q14260; Q6IC53; Q99588; Q99672;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 3.
DT   15-MAR-2017, entry version 186.
DE   RecName: Full=Mitogen-activated protein kinase 12;
DE            Short=MAP kinase 12;
DE            Short=MAPK 12;
DE            EC=2.7.11.24 {ECO:0000269|PubMed:10212242};
DE   AltName: Full=Extracellular signal-regulated kinase 6;
DE            Short=ERK-6;
DE   AltName: Full=Mitogen-activated protein kinase p38 gamma;
DE            Short=MAP kinase p38 gamma;
DE   AltName: Full=Stress-activated protein kinase 3;
GN   Name=MAPK12; Synonyms=ERK6, SAPK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND MUTAGENESIS OF TYR-185.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8633070; DOI=10.1073/pnas.93.9.4355;
RA   Lechner C., Zahalka M.A., Giot J.-F., Moeller N.P.H., Ullrich A.;
RT   "ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast
RT   differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:4355-4359(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Skeletal muscle;
RX   PubMed=9169156; DOI=10.1006/geno.1997.4633;
RA   Goedert M., Hasegawa J., Craxton M., Leversha M.A., Clegg S.;
RT   "Assignment of the human stress-activated protein kinase-3 gene
RT   (SAPK3) to chromosome 22q13.3 by fluorescence in situ hybridization.";
RL   Genomics 41:501-502(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8920915; DOI=10.1006/bbrc.1996.1662;
RA   Li Z., Jiang Y., Ulevitch R.J., Han J.;
RT   "The primary structure of p38 gamma: a new member of p38 group of MAP
RT   kinases.";
RL   Biochem. Biophys. Res. Commun. 228:334-340(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   MET-103.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF ATF2; ELK1 AND MBP, AND ENZYME
RP   REGULATION.
RX   PubMed=9430721; DOI=10.1074/jbc.273.3.1741;
RA   Enslen H., Raingeaud J., Davis R.J.;
RT   "Selective activation of p38 mitogen-activated protein (MAP) kinase
RT   isoforms by the MAP kinase kinases MKK3 and MKK6.";
RL   J. Biol. Chem. 273:1741-1748(1998).
RN   [8]
RP   INTERACTION WITH SNTA1, ENZYME REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND CATALYTIC ACTIVITY.
RX   PubMed=10212242; DOI=10.1074/jbc.274.18.12626;
RA   Hasegawa M., Cuenda A., Spillantini M.G., Thomas G.M.,
RA   Buee-Scherrer V., Cohen P., Goedert M.;
RT   "Stress-activated protein kinase-3 interacts with the PDZ domain of
RT   alpha1-syntrophin. A mechanism for specific substrate recognition.";
RL   J. Biol. Chem. 274:12626-12631(1999).
RN   [9]
RP   PHOSPHORYLATION BY MAP2K6/MKK6.
RX   PubMed=11010976; DOI=10.1074/jbc.M007835200;
RA   Alonso G., Ambrosino C., Jones M., Nebreda A.R.;
RT   "Differential activation of p38 mitogen-activated protein kinase
RT   isoforms depending on signal strength.";
RL   J. Biol. Chem. 275:40641-40648(2000).
RN   [10]
RP   FUNCTION IN REGULATION OF THE G2 CHECKPOINT.
RX   PubMed=10848581; DOI=10.1128/MCB.20.13.4543-4552.2000;
RA   Wang X., McGowan C.H., Zhao M., He L., Downey J.S., Fearns C.,
RA   Wang Y., Huang S., Han J.;
RT   "Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced
RT   cell cycle arrest.";
RL   Mol. Cell. Biol. 20:4543-4552(2000).
RN   [11]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart;
RX   PubMed=11991731; DOI=10.1006/jmcc.2001.1523;
RA   Court N.W., dos Remedios C.G., Cordell J., Bogoyevitch M.A.;
RT   "Cardiac expression and subcellular localization of the p38 mitogen-
RT   activated protein kinase member, stress-activated protein kinase-3
RT   (SAPK3).";
RL   J. Mol. Cell. Cardiol. 34:413-426(2002).
RN   [12]
RP   MUTAGENESIS, SUBCELLULAR LOCATION, AND INTERACTION WITH SH3BP5.
RX   PubMed=12167088; DOI=10.1042/BJ20020553;
RA   Wiltshire C., Matsushita M., Tsukada S., Gillespie D.A., May G.H.;
RT   "A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab
RT   (SH3BP5), associates with mitochondria.";
RL   Biochem. J. 367:577-585(2002).
RN   [13]
RP   FUNCTION.
RX   PubMed=14592936; DOI=10.1152/ajpregu.00563.2003;
RA   Ho R.C., Alcazar O., Fujii N., Hirshman M.F., Goodyear L.J.;
RT   "p38gamma MAPK regulation of glucose transporter expression and
RT   glucose uptake in L6 myotubes and mouse skeletal muscle.";
RL   Am. J. Physiol. 286:R342-R349(2004).
RN   [14]
RP   MUTAGENESIS OF ASP-179 AND PHE-330.
RX   PubMed=15284239; DOI=10.1074/jbc.M404595200;
RA   Diskin R., Askari N., Capone R., Engelberg D., Livnah O.;
RT   "Active mutants of the human p38alpha mitogen-activated protein
RT   kinase.";
RL   J. Biol. Chem. 279:47040-47049(2004).
RN   [15]
RP   FUNCTION, INDUCTION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=17724032; DOI=10.1074/jbc.M703857200;
RA   Qi X., Pohl N.M., Loesch M., Hou S., Li R., Qin J.Z., Cuenda A.,
RA   Chen G.;
RT   "p38alpha antagonizes p38gamma activity through c-Jun-dependent
RT   ubiquitin-proteasome pathways in regulating Ras transformation and
RT   stress response.";
RL   J. Biol. Chem. 282:31398-31408(2007).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF DLG1.
RX   PubMed=20605917; DOI=10.1242/jcs.066514;
RA   Sabio G., Cerezo-Guisado M.I., Del Reino P., Inesta-Vaquera F.A.,
RA   Rousseau S., Arthur J.S., Campbell D.G., Centeno F., Cuenda A.;
RT   "p38gamma regulates interaction of nuclear PSF and RNA with the
RT   tumour-suppressor hDlg in response to osmotic shock.";
RL   J. Cell Sci. 123:2596-2604(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   FUNCTION.
RX   PubMed=21172807; DOI=10.1242/jcs.068254;
RA   Kukkonen-Macchi A., Sicora O., Kaczynska K., Oetken-Lindholm C.,
RA   Pouwels J., Laine L., Kallio M.J.;
RT   "Loss of p38gamma MAPK induces pleiotropic mitotic defects and massive
RT   cell death.";
RL   J. Cell Sci. 124:216-227(2011).
RN   [19]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=21532888; DOI=10.1593/neo.101748;
RA   Meng F., Zhang H., Liu G., Kreike B., Chen W., Sethi S., Miller F.R.,
RA   Wu G.;
RT   "p38gamma mitogen-activated protein kinase contributes to oncogenic
RT   properties maintenance and resistance to poly (ADP-ribose)-polymerase-
RT   1 inhibition in breast cancer.";
RL   Neoplasia 13:472-482(2011).
RN   [20]
RP   REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=20626350; DOI=10.1042/BJ20100323;
RA   Cuadrado A., Nebreda A.R.;
RT   "Mechanisms and functions of p38 MAPK signalling.";
RL   Biochem. J. 429:403-417(2010).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-185, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS), COFACTOR, AND SUBUNIT.
RX   PubMed=10508788; DOI=10.1016/S0969-2126(99)80173-7;
RA   Bellon S., Fitzgibbon M.J., Fox T., Hsiao H.M., Wilson K.P.;
RT   "The structure of phosphorylated p38gamma is monomeric and reveals a
RT   conserved activation-loop conformation.";
RL   Structure 7:1057-1065(1999).
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-103 AND ASN-230.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. MAPK12 is
CC       one of the four p38 MAPKs which play an important role in the
CC       cascades of cellular responses evoked by extracellular stimuli
CC       such as proinflammatory cytokines or physical stress leading to
CC       direct activation of transcription factors such as ELK1 and ATF2.
CC       Accordingly, p38 MAPKs phosphorylate a broad range of proteins and
CC       it has been estimated that they may have approximately 200 to 300
CC       substrates each. Some of the targets are downstream kinases such
CC       as MAPKAPK2, which are activated through phosphorylation and
CC       further phosphorylate additional targets. Plays a role in myoblast
CC       differentiation and also in the down-regulation of cyclin D1 in
CC       response to hypoxia in adrenal cells suggesting MAPK12 may inhibit
CC       cell proliferation while promoting differentiation. Phosphorylates
CC       DLG1. Following osmotic shock, MAPK12 in the cell nucleus
CC       increases its association with nuclear DLG1, thereby causing
CC       dissociation of DLG1-SFPQ complexes. This function is independent
CC       of its catalytic activity and could affect mRNA processing and/or
CC       gene transcription to aid cell adaptation to osmolarity changes in
CC       the environment. Regulates UV-induced checkpoint signaling and
CC       repair of UV-induced DNA damage and G2 arrest after gamma-
CC       radiation exposure. MAPK12 is involved in the regulation of SLC2A1
CC       expression and basal glucose uptake in L6 myotubes; and negatively
CC       regulates SLC2A4 expression and contraction-mediated glucose
CC       uptake in adult skeletal muscle. C-Jun (JUN) phosphorylation is
CC       stimulated by MAPK14 and inhibited by MAPK12, leading to a
CC       distinct AP-1 regulation. MAPK12 is required for the normal
CC       kinetochore localization of PLK1, prevents chromosomal instability
CC       and supports mitotic cell viability. MAPK12-signaling is also
CC       positively regulating the expansion of transient amplifying
CC       myogenic precursor cells during muscle growth and regeneration.
CC       {ECO:0000269|PubMed:10848581, ECO:0000269|PubMed:14592936,
CC       ECO:0000269|PubMed:17724032, ECO:0000269|PubMed:20605917,
CC       ECO:0000269|PubMed:21172807, ECO:0000269|PubMed:8633070,
CC       ECO:0000269|PubMed:9430721}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:10212242}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10508788};
CC       Note=Binds 2 magnesium ions. {ECO:0000269|PubMed:10508788};
CC   -!- ENZYME REGULATION: Activated by phosphorylation on threonine and
CC       tyrosine. MAP2K3/MKK3 and MAP2K6/MKK6 are both essential for the
CC       activation of MAPK12 induced by environmental stress, whereas
CC       MAP2K6/MKK6 is the major MAPK12 activator in response to TNF-
CC       alpha. {ECO:0000269|PubMed:10212242, ECO:0000269|PubMed:9430721}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=37 uM for ATP {ECO:0000269|PubMed:10212242};
CC         KM=313 uM for EGFR substrate peptide
CC         {ECO:0000269|PubMed:10212242};
CC         KM=254 uM for GST-ATF2 {ECO:0000269|PubMed:10212242};
CC   -!- SUBUNIT: Monomer. Interacts with the PDZ domain of the syntrophin
CC       SNTA1. Interacts with SH3BP5. Interacts with LIN7C, SCRIB and
CC       SYNJ2BP (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q16512:PKN1; NbExp=2; IntAct=EBI-602406, EBI-602382;
CC       P29074:PTPN4; NbExp=2; IntAct=EBI-602406, EBI-710431;
CC       Q14160:SCRIB; NbExp=3; IntAct=EBI-602406, EBI-357345;
CC       Q8IUQ4:SIAH1; NbExp=3; IntAct=EBI-602406, EBI-747107;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Mitochondrion.
CC       Note=Mitochondrial when associated with SH3BP5. In skeletal muscle
CC       colocalizes with SNTA1 at the neuromuscular junction and
CC       throughout the sarcolemma (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P53778-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P53778-2; Sequence=VSP_055224;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle and heart.
CC       {ECO:0000269|PubMed:11991731, ECO:0000269|PubMed:8633070}.
CC   -!- INDUCTION: Expression of MAPK12 is down-regulation by MAPK14
CC       activation. {ECO:0000269|PubMed:17724032}.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K3/MKK3
CC       and MAP2K6/MKK6, which activates the enzyme.
CC       {ECO:0000269|PubMed:11010976, ECO:0000269|PubMed:17724032}.
CC   -!- PTM: Ubiquitinated. Ubiquitination leads to degradation by the
CC       proteasome pathway. {ECO:0000269|PubMed:17724032}.
CC   -!- DISEASE: Note=MAPK is overexpressed in highly metastatic breast
CC       cancer cell lines and its expression is preferentially associated
CC       with basal-like and metastatic phenotypes of breast tumor samples.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MAP kinase subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK12ID41290ch22q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X79483; CAA55984.1; -; mRNA.
DR   EMBL; Y10487; CAA71511.1; -; mRNA.
DR   EMBL; U66243; AAB40118.1; -; mRNA.
DR   EMBL; CR456515; CAG30401.1; -; mRNA.
DR   EMBL; AL022328; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015741; AAH15741.1; -; mRNA.
DR   CCDS; CCDS14089.1; -. [P53778-1]
DR   CCDS; CCDS77688.1; -. [P53778-2]
DR   PIR; JC5252; JC5252.
DR   PIR; JC6138; JC6138.
DR   RefSeq; NP_001290181.1; NM_001303252.2. [P53778-2]
DR   RefSeq; NP_002960.2; NM_002969.5. [P53778-1]
DR   UniGene; Hs.432642; -.
DR   PDB; 1CM8; X-ray; 2.40 A; A/B=1-367.
DR   PDB; 4QUM; X-ray; 2.52 A; B=182-190.
DR   PDBsum; 1CM8; -.
DR   PDBsum; 4QUM; -.
DR   ProteinModelPortal; P53778; -.
DR   SMR; P53778; -.
DR   BioGrid; 112207; 25.
DR   DIP; DIP-34241N; -.
DR   IntAct; P53778; 14.
DR   MINT; MINT-90266; -.
DR   STRING; 9606.ENSP00000215659; -.
DR   BindingDB; P53778; -.
DR   ChEMBL; CHEMBL4674; -.
DR   DrugBank; DB05403; CEP-1347.
DR   DrugBank; DB05157; KC706.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB02482; Phosphonothreonine.
DR   GuidetoPHARMACOLOGY; 1501; -.
DR   iPTMnet; P53778; -.
DR   PhosphoSitePlus; P53778; -.
DR   BioMuta; MAPK12; -.
DR   DMDM; 2851522; -.
DR   EPD; P53778; -.
DR   MaxQB; P53778; -.
DR   PaxDb; P53778; -.
DR   PeptideAtlas; P53778; -.
DR   PRIDE; P53778; -.
DR   DNASU; 6300; -.
DR   Ensembl; ENST00000215659; ENSP00000215659; ENSG00000188130. [P53778-1]
DR   Ensembl; ENST00000622558; ENSP00000479972; ENSG00000188130. [P53778-2]
DR   GeneID; 6300; -.
DR   KEGG; hsa:6300; -.
DR   UCSC; uc003bkl.2; human. [P53778-1]
DR   CTD; 6300; -.
DR   DisGeNET; 6300; -.
DR   GeneCards; MAPK12; -.
DR   HGNC; HGNC:6874; MAPK12.
DR   HPA; CAB025483; -.
DR   HPA; HPA054562; -.
DR   MIM; 602399; gene.
DR   neXtProt; NX_P53778; -.
DR   OpenTargets; ENSG00000188130; -.
DR   PharmGKB; PA30619; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   eggNOG; ENOG410XNY0; LUCA.
DR   GeneTree; ENSGT00550000074271; -.
DR   HOGENOM; HOG000233024; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; P53778; -.
DR   KO; K04441; -.
DR   OMA; MKHEKLG; -.
DR   OrthoDB; EOG091G08QL; -.
DR   PhylomeDB; P53778; -.
DR   TreeFam; TF105100; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation.
DR   Reactome; R-HSA-375170; CDO in myogenesis.
DR   Reactome; R-HSA-376172; DSCAM interactions.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   SignaLink; P53778; -.
DR   SIGNOR; P53778; -.
DR   EvolutionaryTrace; P53778; -.
DR   GeneWiki; MAPK12; -.
DR   GenomeRNAi; 6300; -.
DR   PRO; PR:P53778; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000188130; -.
DR   CleanEx; HS_MAPK12; -.
DR   ExpressionAtlas; P53778; baseline and differential.
DR   Genevisible; P53778; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:ProtInc.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007517; P:muscle organ development; TAS:ProtInc.
DR   GO; GO:0045445; P:myoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0010952; P:positive regulation of peptidase activity; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008352; MAPK_p38.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01773; P38MAPKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Complete proteome; Cytoplasm; Kinase; Magnesium; Metal-binding;
KW   Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Stress response; Transcription; Transcription regulation; Transferase;
KW   Ubl conjugation.
FT   CHAIN         1    367       Mitogen-activated protein kinase 12.
FT                                /FTId=PRO_0000186282.
FT   DOMAIN       27    311       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      33     41       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       183    185       TXY.
FT   ACT_SITE    153    153       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING      56     56       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     183    183       Phosphothreonine; by MAP2K3 and MAP2K6.
FT                                {ECO:0000250}.
FT   MOD_RES     185    185       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     142    151       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15461802}.
FT                                /FTId=VSP_055224.
FT   VARIANT     103    103       T -> M (in dbSNP:rs34422484).
FT                                {ECO:0000269|PubMed:15461802,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042265.
FT   VARIANT     230    230       D -> N (in dbSNP:rs35396905).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042266.
FT   VARIANT     244    244       T -> M (in dbSNP:rs2066776).
FT                                /FTId=VAR_012002.
FT   MUTAGEN     179    179       D->A: Emulation of the active state.
FT                                {ECO:0000269|PubMed:15284239}.
FT   MUTAGEN     185    185       Y->F: Loss of activity.
FT                                {ECO:0000269|PubMed:8633070}.
FT   MUTAGEN     330    330       F->S: No effect.
FT                                {ECO:0000269|PubMed:15284239}.
FT   CONFLICT      7      7       A -> T (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   CONFLICT     70     70       R -> L (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   CONFLICT    138    138       L -> M (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   CONFLICT    201    202       MR -> IA (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   CONFLICT    261    261       Y -> N (in Ref. 3; AAB40118).
FT                                {ECO:0000305}.
FT   CONFLICT    297    298       EQ -> DI (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   CONFLICT    300    300       V -> L (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   CONFLICT    305    305       A -> F (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   CONFLICT    307    307       A -> S (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   CONFLICT    332    333       DV -> YF (in Ref. 1; CAA55984).
FT                                {ECO:0000305}.
FT   STRAND       17     21       {ECO:0000244|PDB:1CM8}.
FT   STRAND       24     32       {ECO:0000244|PDB:1CM8}.
FT   STRAND       41     46       {ECO:0000244|PDB:1CM8}.
FT   TURN         47     49       {ECO:0000244|PDB:1CM8}.
FT   STRAND       52     57       {ECO:0000244|PDB:1CM8}.
FT   HELIX        65     80       {ECO:0000244|PDB:1CM8}.
FT   STRAND       90     93       {ECO:0000244|PDB:1CM8}.
FT   TURN         99    101       {ECO:0000244|PDB:1CM8}.
FT   STRAND      106    110       {ECO:0000244|PDB:1CM8}.
FT   STRAND      113    115       {ECO:0000244|PDB:1CM8}.
FT   HELIX       116    122       {ECO:0000244|PDB:1CM8}.
FT   HELIX       127    146       {ECO:0000244|PDB:1CM8}.
FT   HELIX       156    158       {ECO:0000244|PDB:1CM8}.
FT   STRAND      159    161       {ECO:0000244|PDB:1CM8}.
FT   STRAND      167    169       {ECO:0000244|PDB:1CM8}.
FT   HELIX       189    191       {ECO:0000244|PDB:1CM8}.
FT   HELIX       195    198       {ECO:0000244|PDB:1CM8}.
FT   TURN        199    201       {ECO:0000244|PDB:1CM8}.
FT   HELIX       207    221       {ECO:0000244|PDB:1CM8}.
FT   HELIX       231    242       {ECO:0000244|PDB:1CM8}.
FT   HELIX       247    251       {ECO:0000244|PDB:1CM8}.
FT   HELIX       256    264       {ECO:0000244|PDB:1CM8}.
FT   HELIX       273    275       {ECO:0000244|PDB:1CM8}.
FT   HELIX       282    291       {ECO:0000244|PDB:1CM8}.
FT   TURN        296    298       {ECO:0000244|PDB:1CM8}.
FT   HELIX       302    307       {ECO:0000244|PDB:1CM8}.
FT   HELIX       309    311       {ECO:0000244|PDB:1CM8}.
FT   TURN        312    314       {ECO:0000244|PDB:1CM8}.
FT   HELIX       337    349       {ECO:0000244|PDB:1CM8}.
SQ   SEQUENCE   367 AA;  41940 MW;  EF680401D8E40610 CRC64;
     MSSPPPARSG FYRQEVTKTA WEVRAVYRDL QPVGSGAYGA VCSAVDGRTG AKVAIKKLYR
     PFQSELFAKR AYRELRLLKH MRHENVIGLL DVFTPDETLD DFTDFYLVMP FMGTDLGKLM
     KHEKLGEDRI QFLVYQMLKG LRYIHAAGII HRDLKPGNLA VNEDCELKIL DFGLARQADS
     EMTGYVVTRW YRAPEVILNW MRYTQTVDIW SVGCIMAEMI TGKTLFKGSD HLDQLKEIMK
     VTGTPPAEFV QRLQSDEAKN YMKGLPELEK KDFASILTNA SPLAVNLLEK MLVLDAEQRV
     TAGEALAHPY FESLHDTEDE PQVQKYDDSF DDVDRTLDEW KRVTYKEVLS FKPPRQLGAR
     VSKETPL
//
